.svg)
The inherited risk of prostate cancer can come from either your mother’s side or your father’s side of the family. Many men are surprised to learn that their mother’s side matters too.
Approximately 5 to 10% of prostate cancer cases are caused by inherited gene changes. Because these gene changes can be carried on chromosomes inherited from both parents, a man whose mother carries a BRCA2 mutation faces exactly the same elevated prostate cancer risk as a man whose father carries it. Most men are never told this.
This guide explains how prostate cancer is inherited, which genes are involved, how family history affects your specific risk level, and what proactive steps are available to men at elevated hereditary risk.
Hereditary prostate cancer follows the same rules as other inherited conditions. Genes come in pairs, one copy from each parent. Certain gene changes, such as a BRCA2 mutation, can be carried by someone who never develops cancer and still be passed on to their children. This means a man's mother can carry a BRCA2 mutation, most commonly discussed in the context of breast and ovarian cancer, and pass it to her son, significantly raising his prostate cancer risk.
Roughly 1 in 7 men will be diagnosed with prostate cancer in their lifetime, according to the American Cancer Society. Of those cases, approximately 5-10% are linked to inherited gene changes. The rest develop due to a combination of age, hormonal factors, lifestyle, and random DNA changes over time.
Hereditary prostate cancer typically involves changes in genes that help repair damaged DNA or regulate how cells grow. When these genes are working normally, they act as a natural brake on uncontrolled cell growth. When a harmful gene change is present, that brake is weakened, and the lifetime probability of developing prostate cancer rises.
Because these gene changes are inherited, meaning they are present in every cell of the body from birth, they can be identified through genetic testing long before cancer develops. That gives men at elevated risk the opportunity to pursue proactive monitoring at the right time.
BRCA2 is a gene that most people associate with breast and ovarian cancer in women. But BRCA2 mutations also significantly raise prostate cancer risk in men, and they can be inherited from either parent. A man with a BRCA2 mutation faces a prostate cancer lifetime risk approximately 2 to 6 times higher than the general population, according to the National Cancer Institute. He also faces an elevated risk of breast cancer and pancreatic cancer. (NCI, Prostate Cancer Genetics)
Because BRCA2 is so strongly associated with women's cancers in public awareness, it is frequently not discussed in the context of men's health. This leaves male BRCA2 mutation carriers without the information they need to make informed decisions about screening.
Several genes are associated with elevated hereditary prostate cancer risk. Which gene is involved matters because it affects how high your risk is and whether the risk of other cancers is also elevated.
Both BRCA genes are involved in DNA repair. When they have harmful changes, the body's ability to prevent uncontrolled cell growth is compromised:
A positive BRCA1 or BRCA2 result in a mother, sister, aunt, or grandmother is just as relevant to a man’s prostate cancer risk as a result on his father’s side. That is why family history should be reviewed broadly, not just for prostate cancer in men, but for related cancers across both sides of the family..
Lynch syndrome is caused by changes in mismatch repair genes, including MLH1, MSH2, MSH6, and PMS2. It is most well known for raising colorectal and endometrial cancer risk, but it also moderately elevates prostate cancer risk. Men with Lynch syndrome may be recommended for prostate cancer surveillance as part of their broader cancer monitoring plan. (CDC Genomics)
HOXB13 is a prostate-specific gene. Certain changes in HOXB13, particularly a variant called G84E, are associated with elevated hereditary prostate cancer risk, especially for early-onset prostate cancer. HOXB13 variants are relatively rare but can be identified through comprehensive hereditary cancer panels.
Family history is one of the strongest known risk factors for prostate cancer. The American Cancer Society identifies the following risk escalations based on family patterns: (American Cancer Society)
The age at which a family member was diagnosed is a meaningful signal. Prostate cancer diagnosed at an unusually young age, before 55, is more likely to have a hereditary cause than cancer diagnosed in a man's 70s or 80s. When multiple relatives are diagnosed early, the probability of a hereditary mutation increases substantially.
For men with a first-degree relative diagnosed before 55, clinical guidelines often recommend beginning prostate cancer screening discussions with a physician earlier than standard population recommendations.
For men with a family history that suggests hereditary prostate cancer risk, genetic testing can provide something that PSA testing and standard screening cannot: a definitive answer about whether a known inherited gene change is present. That answer matters because the clinical response to a confirmed mutation differs from that to a general family history pattern.
National Comprehensive Cancer Network (NCCN) guidelines recommend genetic testing for men with:
Genetic testing identifies the specific mutation, not just the risk pattern, which allows clinical decisions to be tailored to the gene involved. Your genetic information is private and protected, accessible only to you and your care team.
For men at elevated hereditary prostate cancer risk, standard population screening guidelines may be insufficient. Men with a confirmed BRCA2 mutation or a strong family history are generally recommended for earlier and more intensive surveillance:
Not exactly, but it can look that way. An inherited gene mutation can be present in a family member who never develops prostate cancer, either because they died of something else first, or simply because carrying a mutation does not guarantee cancer will develop. Their children and grandchildren may still have inherited the same mutation. This is one reason family history alone gives an incomplete picture, and why genetic testing can identify mutations that appear to have skipped a generation.
Yes. If your mother carries a BRCA2 mutation, you have a 50% chance of having inherited it. A male BRCA2 carrier faces significantly elevated prostate cancer risk, the same as if the mutation came from a father. This is one of the most important and least understood aspects of hereditary prostate cancer. Male relatives of women with BRCA mutations are often not advised to pursue genetic testing, leaving them unaware of their own elevated risk.
Yes. They serve completely different purposes. PSA testing measures a protein produced by the prostate gland and is used as a screening tool to detect signs of prostate cancer that may already be present. Germline genetic testing analyzes DNA to identify inherited gene changes that raise the risk of developing prostate cancer in the future. This type of genetic testing is done once. PSA testing is repeated periodically. They are complementary tools, not interchangeable ones.
A father or brother with prostate cancer is not just a difficult family experience. It is biological information. And when it comes to hereditary cancer risk, information is something you can act on before cancer acts on you.
Men with a meaningful family history of prostate cancer, particularly early-onset cases, multiple affected relatives, or a family history of BRCA-related cancers in female relatives, have access to genetic tools that can clarify their inherited risk and guide smarter surveillance decisions.
Optimize your health. Start with what your DNA already knows. Explore Kadance membership and gain access to hereditary cancer risk testing, genetic counseling, and the precision health framework to make proactive decisions.